Comparison of effective dose and lifetime risk of cancer incidence of CT attenuation correction acquisitions and radiopharmaceutical administration for myocardial perfusion imaging

Tootell, AK, Szczepura, K and Hogg, P 2014, 'Comparison of effective dose and lifetime risk of cancer incidence of CT attenuation correction acquisitions and radiopharmaceutical administration for myocardial perfusion imaging' , The British Journal of Radiology, 87 (1041) , p. 20140110.

Full text not available from this repository.

Abstract

Objective: To measure the organ dose and calculate effective dose from CT attenuation correction (CTAC) acquisitions from four commonly used gamma camera single photon emission CT/CT systems. Methods: CTAC dosimetry data was collected using thermoluminescent dosemeters on GE Healthcare's Infinia™ Hawkeye™ (GE Healthcare, Buckinghamshire, UK) four- and single-slice systems, Siemens Symbia™ T6 (Siemens Healthcare, Erlangen, Germany) and the Philips Precedence (Philips Healthcare, Amsterdam, Netherlands). Organ and effective dose from the administration of 99mTc-tetrofosmin and 99mTc-sestamibi were calculated using International Commission of Radiological Protection reports 80 and 106. Using these data, the lifetime biological risk was calculated. Results: The Siemens Symbia gave the lowest CTAC dose (1.8mSv) followed by the GE Infinia Hawkeye single- slice (1.9mSv), GE Infinia Hawkeye four-slice (2.5mSv) and Philips Precedence v. 3.0. Doses were significantly lower than the calculated doses from radiopharmaceutical administration (11 and 14mSv for 99mTc-tetrofosmin and 99mTc-sestamibi, respectively). Overall lifetime biological risks were lower, which suggests that using CTAC data posed minimal risk to the patient. Comparison of data for breast tissue demonstrated a higher risk than that from the radiopharmaceutical administration. Conclusion: CTAC doses were confirmed to be much lower than those from radiopharmaceutical administration. The localized nature of the CTAC exposure compared to the radiopharmaceutical biological distribution indicated dose and risk to the breast to be higher. Advances in knowledge: This research proved that CTAC is a comparatively low-dose acquisition. However, it has been shown that there is increased risk for breast tissue especially in the younger patients. As per legislation, justification is required and CTAC should only be used in situations that demonstrate sufficient net benefit.

Item Type: Article
Schools: Schools > School of Health Sciences
Journal or Publication Title: The British Journal of Radiology
Publisher: British Institute of Radiology
ISSN: 0007-1285
Depositing User: WM Taylor
Date Deposited: 23 Nov 2016 11:34
Last Modified: 23 Nov 2016 11:34
URI: http://usir.salford.ac.uk/id/eprint/40849

Actions (login required)

Edit record (repository staff only) Edit record (repository staff only)